[Optimization of hypotensive therapy in hypertensive patients with new beta-1 selective long-acting adrenoblocker].
20 hypertensive subjects entered the trial of kerlon (Searle, USA). Central hemodynamics was studied by tetrapolar chest rheography according to J. Franz. Therapeutic response to beta-1-adrenoblocker kerlon in hypertension was assessed by hemodynamic indices and acute pharmacological test. The effect was found to depend on the initial hemocirculation type. In hyperkinetic hemodynamics lowering of blood pressure was due to diminution of the cardiac index, in eukinetic and hypokinetic types- to a decrease in the total peripheral vascular resistance.
L K
LK
Karazhanova
A S
AS
Abdrakhmanov
D058671:Adrenergic beta-1 Receptor Antagonists; D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use*; D015784:Betaxolol / Q000627:therapeutic use*; D001794:Blood Pressure / Q000187:drug effects*; D003692:Delayed-Action Preparations; D005080:Exercise Test; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D006973:Hypertension / Q000188:drug therapy* / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D016896:Treatment Outcome
D058671:Adrenergic beta-1 Receptor Antagonists; D000319:Adrenergic beta-Antagonists; D003692:Delayed-Action Preparations; D015784:Betaxolol
Puti optimizatsii gipotenzivnoĭ terapii bol'nykh gipertonicheskoĭ bolezn'iu novym beta1-selektivnym adrenoblokatorom prolongirovannogo deĭstviia.